The Effect of White Tea in Healthy Human Subjects
Effect of White Tea (Camellia Sinensis L.) Beverages on Anthropometric, Hematological, Biochemical and First Line Antioxidant Enzymes Activity of Healthy Human (Superoxide Dismutase, and Glutathione Peroxidase)
1 other identifier
interventional
19
1 country
1
Brief Summary
This clinical study aims to determine the effects of consuming white tea infusion (Camellia sinensis) on healthy subjects over a period of 14 days. The main questions it aims to answer are:
- 1.Determine the effect of white tea consumption on the anthropometry of healthy subjects.
- 2.Determine the effect of white tea consumption on the biochemical parameters of healthy subjects.
- 3.Determine the effect of white tea consumption on hematology parameters that are related to anemia case in healthy subjects.
- 4.Determine the effect of white tea consumption on the activity of first-line antioxidant enzymes in healthy subjects
- 5.Follow the washout stage for 7 days
- 6.Drink white tea infusion every day for 14 days.
- 7.Follow up to monitor adverse effects after consuming white tea; this stage will be conducted for 7 days.
- 8.Report all food and beverages consumed by respondents during the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 22, 2025
CompletedFirst Submitted
Initial submission to the registry
September 12, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 27, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2025
CompletedFirst Posted
Study publicly available on registry
January 15, 2026
CompletedApril 17, 2026
April 1, 2026
1 month
September 12, 2025
April 15, 2026
Conditions
Outcome Measures
Primary Outcomes (7)
Antioxidant Enzymes Analysis
Comparing the antioxidant activity values of enzymes including superoxide dismutase, catalase, and glutathione peroxidase in pre and post white tea treatment (day 0 and day 15). The increased activity of antioxidant enzymes signifies an enhancement in the body's capability to combat free radicals. The analysis will be conducted using a reagent kit to obtain the antioxidant enzyme activity values in the respondents' serum. All antioxidant enzyme parameter values are expressed in U/mL.
14 days
Liver Function Analysis
The effect of the product on liver function will be analysed based on SGOT and SGPT values. A drastic increase compared to the pre-intervention level indicates potential toxicity. Both parameters will be expressed in units of ukat/L.
14 days
estimated Glomerular filtration rate
A drastic decrease in eGFR indicates the potential toxicity of white tea beverages. eGFR results of respondents will be expressed in mL/min/1.73m2
14 days
Lipid profile measurement
The effect of product administration on lipid profile was assessed by measuring total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) parameters. Product effectiveness was determined based on the stability or decrease in total cholesterol, triglycerides, and LDL values, as well as an increase in HDL values post-treatment compared to pre-treatment values. Total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) will be expressed in mmol/L
14 days
Fasting blood glucose measurement
Fasting blood glucose will be expressed in mmol/L
14 days
Serum creatinine Analysis
An elevated serum creatinine level is an indication of potential toxicity associated with white tea consumption. Serum creatinine level will be expressed in umol/L
14 days
Blood Urea Nitrogen Analysis
An elevated blood urea nitrogen level is an indication of potential toxicity associated with white tea consumption. The parameter will be written in units of mmol/L
14 days
Secondary Outcomes (12)
Body Weight Measurement
14 days
Body Height Measurement
14 days
Body Mass Index
14 days
Waist Circumference Measurement
14 days
Blood Pressure Measurement
14 days
- +7 more secondary outcomes
Study Arms (1)
White tea intervention
EXPERIMENTALNineteen respondents will be given 200 mL of white tea (4 grams of white tea sample in 200 mL of water at a temperature of 95-98°C) for 14 days after a 7-day washout period. In the final stage, all respondents will undergo an observation phase. In the final stage, all respondents are required to submit updates on their physical condition. If they experience discomfort such as nausea, dizziness, or general unease, the respondents will be examined by the research physician. In our study, no control group was used. To demonstrate the effect of white tea on the respondents' health condition, we compared the results before and after the treatment.
Interventions
1. White tea infusion was prepared by brewing 4 grams of white tea in 200 mL of hot water. 2. Healthy respondents were asked to consume the white tea infusion for 14 days. 3. The focus of this study was to observe the effect of white tea infusion on antioxidant enzyme activity and its relationship with anthropometric, biochemical, and haematological parameters.
Eligibility Criteria
You may qualify if:
- The participants are the community around Padjadjaran University with an age range of 20 - 35 years old. Female respondents were unmarried.
- The participants are non-smoker.
- The participants should have no history of anemia, chronic disease, hepatic and renal dysfunction.
- The participants are willing to follow the research process until its finish by signing an informed consent form.
You may not qualify if:
- The participants who are undergoing drug therapy and taking vitamin supplements.
- The participants who failed due to illness or are unable to continue the examination to the end.
- Respondents with pre-treatment biochemical results not within the normal range
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Pharmacy, Padjadjaran University
Sumedang, West Java, 45363, Indonesia
Study Officials
- STUDY DIRECTOR
Gofarana Wilar, Ph.D.
Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 12, 2025
First Posted
January 15, 2026
Study Start
August 22, 2025
Primary Completion
September 27, 2025
Study Completion
December 30, 2025
Last Updated
April 17, 2026
Record last verified: 2026-04